Analysis for the primary end point showed a trend toward lower rates of abnormal post-PCI creatine kinase-MB mass values in the heparin-plus-eptifibatide group ( 18 [ 41 % ] ) versus the heparin-alone group ( 26 [ 55 % ] , relative risk 0.74 [ 95 % CI 0.48-1 .15 ] , P = .169 ) .
